Abstract
Objective
To evaluate extent of disease estimation of abbreviated protocol (ap) magnetic resonance imaging (MRI) compared with full protocol (fp) MRI in newly diagnosed breast cancer.
Methods
In this institutional review board–approved, Health Insurance Portability and Accountability Act–compliant, retrospective study of women with breast cancer who underwent pretreatment fpMRI on a 3 Tesla MRI in 2013, axial fat-saturated pre- and first postcontrast T1, maximum-intensity projection, and subtraction sequences were interpreted independently by three breast radiologists in two sessions, without and with prior imaging, respectively. Agreement was calculated using Cohen’s kappa. Interpretations were compared with histology or clinical stability. Diagnostic performances were compared using Bennett’s statistic. P < 0.05 was significant.
Results
Eighty-one women (mean age 56 years, range 32–92 years), 116 lesions, and 95 cancers (mean size 27 mm, range 4–110 mm) were included. Agreement among radiologists for lesion assessment was excellent (0.83). apMRI cancer detection improved with prior imaging (mean sensitivity from 95% to 99%, specificity from 91% to 97%, positive predictive value [PPV] from 92% to 98%, and negative predictive value [NPV] from 95% to 99%) versus fpMRI (sensitivity 98% [93/95], specificity 94% [76/81], PPV 95% [93/98], and NPV 97% [76/78]). apMRI detected all multifocal, multicentric, and contralateral disease seen in 19% (15/81) of women to the same extent as fpMRI. apMRI axillary metastases detection improved with prior imaging (mean sensitivity from 78% to 86%, specificity from 90% to 92%, PPV from 76% to 82%, and NPV from 89% to 94%) versus fpMRI (sensitivity 71% [17/24], specificity 88% [51/58]), PPV 71% [17/24], and NPV 88% [51/58]).
Conclusion
apMRI may be acceptable for women with newly diagnosed cancer.
Newly Diagnosed Breast Cancer: Comparison of Contrast-enhanced Spectral Mammography and Breast MR Imaging in the Evaluation of Extent of Disease
